ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM
Abstract Number: 2210
Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2077
Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III
10:30AM-12:30PM
Abstract Number: 1964
Comparison of Knee Minimum Joint Space Width Measurements Using Deep Learning in Patients with Rheumatoid Arthritis and Osteoarthritis Undergoing Total Knee Arthroplasty
Imaging of Rheumatic Diseases Poster II
10:30AM-12:30PM
Abstract Number: 2257
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
RA – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 2001
Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis
Immunological Complications of Medical Therapy Poster
10:30AM-12:30PM
Abstract Number: 1963
Computer Vision on Standardized Smartphone Photographs as a Screening Tool for Inflammatory Arthritis of the Hand: Results from an Indian Patient Cohort
Imaging of Rheumatic Diseases Poster II
10:30AM-12:30PM
Abstract Number: 2214
Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2153
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Patient Outcomes, Preferences, & Attitudes Poster III
10:30AM-12:30PM
Abstract Number: 2448
Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function
Systemic Sclerosis & Related Disorders – Clinical Poster III
10:30AM-12:30PM
Abstract Number: 1870
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Epidemiology & Public Health Poster III
10:30AM-12:30PM
Abstract Number: 2022
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III
10:30AM-12:30PM
Abstract Number: 2473
Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study
Systemic Sclerosis & Related Disorders – Clinical Poster III
10:30AM-12:30PM
Abstract Number: 2094
Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs
Osteoarthritis – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1881
Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022
Epidemiology & Public Health Poster III
10:30AM-12:30PM
Abstract Number: 2114
CT and DXA Bone Fragility Evaluation After Bariatric Surgery
Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster
  • «Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 61
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology